Gastroenterology · Proton Pump InhibitorRegulatory Approvalregulatorymid-term

FDA Grants Approval for Pantoprazole Sodium ANDA219973

Importance7/ 10

ActionMonitor

AutoResearch

Multi-agent research across ingested FDA, EMA, MHRA, PMDA, PubMed, ClinicalTrials.gov, company documents, and Humanexa signals.

Last run 7/28/2026, 6:31:30 PM

Assessment confidence: 63% · The main uncertainty is timing and magnitude of competitive and regulatory follow-through.

Executive Thesis

The FDA's approval of Pantoprazole Sodium ANDA219973 is significant as it allows Shuangcheng to enter the competitive proton pump inhibitor market. This could shift market dynamics and necessitate strategic adjustments from existing competitors. Regulatory context from FDA (FDA AP — PANTOPRAZOLE SODIUM (ORIG)) supports the near-term read. Assessment grounded in 19 ranked evidence items (8 high-relevance).

Strategic Assessment

Portfolio teams should assess the implications of this approval on market share and pricing strategies in the gastroenterology segment. The strongest clinical anchor is A Study on the Effect of Food and Proton Pump Inhibitor on the Pharmacokinetics of HMPL-760 Capsules (ClinicalTrials.gov), moderate corpus alignment. In Gastroenterology · Proton Pump Inhibitor, 7 regulatory and 2 competitive items passed relevance filtering for Shuangcheng.

Competitive Pressure

The most relevant competitive pressure comes from FDA Grants Priority Review for TZIELD (Teplizumab) Supplement (Humanexa Signals) — mechanism alignment (io ). Secondary pressure from FDA grants Priority Review to Roche’s Gazyva/Gazyvaro for primary membranous nephropathy. This approval may enhance Shuangcheng's position in the proton pump inhibitor market, potentially impacting competitors.

Regulatory Outlook

Regulatory risk is concentrated around FDA AP — PANTOPRAZOLE SODIUM (ORIG) (FDA). Entity match (shuangcheng); Regulatory pathway relevance (nda). The approval indicates compliance with FDA standards, but ongoing monitoring of market strategies will be essential to assess regulatory implications on competition.

Key Risks

Elevated medium regulatory exposure for Shuangcheng could delay market entry or constrain labeling if agency review intensifies.

Key Opportunities

Shuangcheng's entry may affect pricing and market share for existing players in the gastroenterology segment, potentially leading to revenue fluctuations.
Upside for Shuangcheng may improve if A Study on the Effect of Food and Proton Pump Inhibitor on the Pharmacokinetics of HMPL-760 Capsules (ClinicalTrials.gov) delivers favorable follow-through.
On July 24, FDA approved Tylenol with Naproxen (acetaminophen 325 mg/naproxen sodium 110 mg tablets), the first fixed-dose combination product to pair acetaminophen with naproxen sodium in a single combination tablet for up to 12 hours of pain relief.
Upside for Shuangcheng may improve if The Efficacy and Safety of Narlumosbart in Combination With Stereotactic Body Radiation Therapy to Improve the Efficacy of First-line Chemotherapy Combined With Immunotherapy in Patients With Bone Met (ClinicalTrials.gov) delivers favorable follow-through.
Portfolio teams should assess the implications of this approval on market share and pricing strategies in the gastroenterology segment.

What Would Change This Assessment

This becomes more urgent if Monitor market entry strategies and sales performance of Pantoprazole Sodium by Shuangcheng post-approval.
Timeline shift beyond mid term would change urgency.
A competitor label expansion or pivotal readout in the same sub-indication would increase competitive pressure.

Supporting Evidence

FDA AP — PANTOPRAZOLE SODIUM (ORIG)
FDAhigh relevance
Entity match (shuangcheng); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — PANTOPRAZOLE SODIUM (SUPPL)
FDAhigh relevance
Entity match (pantoprazole sodium); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — DICLOFENAC SODIUM (SUPPL)
FDAhigh relevance
Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — DEXAMETHASONE SODIUM PHOSPHATE (SUPPL)
FDAhigh relevance
Regulatory pathway relevance (nda)
FDA document
View source
Advancing Generic Drug Development: Leveraging Model-Integrated Evidence (MIE) in the Development & Approval of Generic Drugs - 08/27/2026
FDAhigh relevance
Regulatory pathway relevance (approval)
FDA document
View source
FDA AP — HEPARIN SODIUM PRESERVATIVE FREE (SUPPL)
FDAhigh relevance
Regulatory pathway relevance (nda)
FDA document
View source
FDA Approves First Nonprescription Fixed-Dose Combination of Acetaminophen and Naproxen Sodium for 12-Hour Pain Relief
FDAmedium relevance
Moderate corpus alignment
FDA document
View source

A Study on the Effect of Food and Proton Pump Inhibitor on the Pharmacokinetics of HMPL-760 Capsules
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Hydrus® Microstent New Enrollment Post-Approval Study
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Real-World Study of IL-23 Inhibitors in Active Crohn's Disease
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
A Study to Evaluate the Safety, Tolerability and the Effects of Ixodes Ricinus-Contact Phase Inhibitor (Ir-CPI) in Adult Patients With Spontaneous Intracerebral Haemorrhage
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
The Efficacy and Safety of Narlumosbart in Combination With Stereotactic Body Radiation Therapy to Improve the Efficacy of First-line Chemotherapy Combined With Immunotherapy in Patients With Bone Met
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Urinary Vitamin C Loss in Diabetic Subjects
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source

FDA Grants Priority Review for TZIELD (Teplizumab) Supplement
Humanexa Signalshigh relevance
Mechanism alignment (IO )
FDA grants Priority Review to Roche’s Gazyva/Gazyvaro for primary membranous nephropathy
Humanexa Signalshigh relevance
Sponsor/company relevance (Roche)

Self-perceived learning outcomes of academic detailing discussing rational therapy with proton pump inhibitors among general practitioners in Norway.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Efficacy and drug survival after transitioning to IL-17 inhibitors in patients with psoriasis who did not respond to IL-23 inhibitors: analysis from the BIOREP registry.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Preclinical characterization of HEC116094, an oral inhibitor of the influenza A virus polymerase PB2 subunit.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Recent advances in functional studies of coronavirus NSP13 helicase and challenges in inhibitor development.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source

Regunera

Precedents · guidance

Reg

Loading regulatory precedents…

View full regulatory analysis

Competitiva

Competitors · threats

Intel

Loading competitive findings…

View full competitive analysis

Why this matters

Affected entities

Shuangcheng
Pantoprazole Sodium

Commercial impact

medium

Shuangcheng's entry may affect pricing and market share for existing players in the gastroenterology segment, potentially leading to revenue fluctuations.

Regulatory impact

medium

The approval indicates compliance with FDA standards, but ongoing monitoring of market strategies will be essential to assess regulatory implications on competition.

What to watch

Monitor market entry strategies and sales performance of Pantoprazole Sodium by Shuangcheng post-approval.

Recommended action

Monitor

Track for follow-up milestones; no immediate action required.